Back

Evolocumab early reduces Interleukin-1β/Interleukin-17A and improves left ventricular function in ST-segment elevation myocardial infarction: an observational study in the real world

29 August 2026 (16:15 - 17:00)
Organised by: Logo
Congress Presentation Part of: Emerging lipid-lowering therapeutic modalities Lipid-Lowering Agents ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Professor Jing Gao

Tianjin Chest Hospital, Tianjin (China)

5 More presentations in this session

Presentation thumbnail
Apolipoprotein and inflammatory biomarker changes following marked triglyceride reduction with the GalNAc-conjugated APOC3 siRNA RBD5044
Ms S. Nilsson (Gothenburg, SE)
Abstract
Presentation thumbnail
RNA targeted therapies for lipoprotein(a) lowering: systematic review and meta analysis of siRNA and antisense oligonucleotides
Doctor B. Buot (Quezon City, PH)
Abstract
Presentation thumbnail
Dose-related effects of olezarsen in hypertriglyceridaemia: a systematic review and meta-analysis of 2,610 patients
Miss S. Martinez-Topete (Tijuana, MX)
Abstract
Presentation thumbnail
Comparative effectiveness of probucol versus ezetimibe in statin-treated patients with established atherosclerotic cardiovascular disease
Doctor L. Liu (Tianjin, CN)
Abstract
Presentation thumbnail
Design and baseline data of AZURE-HeFH, a phase 3 study assessing the effect of the oral PCSK9 inhibitor laroprovstat on LDL cholesterol in patients with heterozygous familial hypercholesterolaemia
Doctor E. Stroes (Amsterdam, NL)
Abstract

Access the full session

Session thumbnail
Emerging lipid-lowering therapeutic modalities

The Event

Event poster

ESC Congress 2026

29 August 2026 16:15 CET
You may be interested in
thumbnail
Congress Presentation
Interleukin-1 blockade with Anakinra in ST-segment elevation acute myocardial infarction: Results from the VCUART3 study
3 September 2019
thumbnail
Congress Presentation
Time course of LDL-C lowering after initiation of PCSK9 inhibition or bempedoic acid in atherosclerotic cardiovascular disease
20 March 2026
thumbnail
Congress Presentation
Association between initiation of sacubitril/valsartan and improved left ventricular ejection fraction in the real world
30 June 2021
thumbnail
Congress Presentation
Potential implication of microRNA21 and matrix metalloproteinases in myocardial and arterial function in patients with coronary disease and type-2 diabetes at baseline and 1-year follow up
13 December 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources